Amgen reported $10.4 billion in Q3 sales, surpassing forecasts and raising full-year guidance.
Despite operational success, share prices declined due to concerns over patent expirations and pipeline delays.
Revenue stability is offset by uncertainty surrounding the weight-loss drug MariTide and upcoming patent cliffs.
Amgen reported third-quarter sales of $10.4 billion, beating expectations and raising its full-year outlook despite a share price dip driven by patent expirations and pipeline uncertainty regarding it
ChemBrief